Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pemetrexed (Alimta): a novel multitargeted antifolate agent.

Alex A Adjei1

  • 1Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA. adjei.alex@mayo.edu

Expert Review of Anticancer Therapy
|May 2, 2003
PubMed
Summary

Pemetrexed, a novel antifolate, shows broad antitumor activity across various solid tumors. Folate and vitamin B12 supplementation effectively reduces its toxicities without impacting efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The Impact of Immunotherapy on Incidence of Second Primary Malignancies: A Surrogate for Antitumor Surveillance Activation.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The Perils of AI-Generated Peer Review.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

20 Years of Breakthroughs: Transforming the Fight Against Thoracic Malignancies.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Long-term outcomes of Extensive-Stage small cell lung cancer treated with chemotherapy or Chemo-immunotherapy: A propensity score adjusted cohort study.

Lung cancer (Amsterdam, Netherlands)·2025

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Pemetrexed is a novel multitargeted antifolate drug.
  • It inhibits key enzymes in folate metabolism, purine, and pyrimidine synthesis, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.

Purpose of the Study:

  • To review the biochemistry and clinical activity of pemetrexed.
  • To discuss its efficacy in various solid tumors and its safety profile.

Main Methods:

  • Review of Phase II and Phase III clinical trials.
  • Analysis of pemetrexed's mechanism of action and metabolic pathways.

Main Results:

  • Pemetrexed demonstrated broad antitumor activity in Phase II trials for mesothelioma, non-small cell lung cancer, breast, cervical, colorectal, head and neck, and bladder cancers.
  • A Phase III study showed pemetrexed plus cisplatin superiority over cisplatin alone in mesothelioma.
  • Significant toxicities (myelosuppression, mucositis) were ameliorated by folate and vitamin B12 supplementation without compromising efficacy.

Conclusions:

  • Pemetrexed is an effective antifolate agent with broad antitumor activity.
  • Vitamin supplementation is crucial for managing pemetrexed's toxicities, improving patient tolerability.
  • Pemetrexed, particularly in combination therapy, represents a significant advancement in treating various solid tumors.

Related Experiment Videos